1. Home
  2. OSPN vs ALT Comparison

OSPN vs ALT Comparison

Compare OSPN & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OneSpan Inc.

OSPN

OneSpan Inc.

HOLD

Current Price

$10.98

Market Cap

390.0M

Sector

Technology

ML Signal

HOLD

Logo Altimmune Inc.

ALT

Altimmune Inc.

HOLD

Current Price

$3.22

Market Cap

421.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OSPN
ALT
Founded
1991
1997
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
390.0M
421.5M
IPO Year
2000
2005

Fundamental Metrics

Financial Performance
Metric
OSPN
ALT
Price
$10.98
$3.22
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
6
Target Price
$16.67
$17.67
AVG Volume (30 Days)
530.4K
2.6M
Earning Date
04-30-2026
05-12-2026
Dividend Yield
4.91%
N/A
EPS Growth
28.77
25.37
EPS
1.88
N/A
Revenue
$243,180,000.00
$41,000.00
Revenue This Year
$3.22
N/A
Revenue Next Year
$3.16
N/A
P/E Ratio
$5.64
N/A
Revenue Growth
N/A
105.00
52 Week Low
$10.07
$2.87
52 Week High
$18.13
$7.73

Technical Indicators

Market Signals
Indicator
OSPN
ALT
Relative Strength Index (RSI) 54.07 40.69
Support Level $10.20 $2.89
Resistance Level $10.98 $4.25
Average True Range (ATR) 0.38 0.17
MACD 0.07 0.05
Stochastic Oscillator 67.80 54.48

Price Performance

Historical Comparison
OSPN
ALT

About OSPN OneSpan Inc.

OneSpan Inc is a provider of information technology security solutions for banking and financial services and application security markets. The company build secure, seamless, and trusted digital experiences through two solution portfolios: Cybersecurity solutions engaged in protecting identities, securing mobile apps, and safeguarding access through high-assurance authentication, threat intelligence, fraud prevention, and robust mobile app protection, defending users, devices, and applications against sophisticated attacks, while Digital agreement solutions focuses on streamlining workflows with secure e-signatures, identity verification, and smart digital forms, built to enable speed, compliance and other customer experiences.

About ALT Altimmune Inc.

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: